| [1] |
Friesema EC, Ganguly S, Abdalla A, et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter[J]. J Biol Chem, 2003, 278(41): 40128-40135.
|
| [2] |
Dumitrescu AM, Liao XH, Best TB, et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene[J]. Am J Hum Genet, 2004, 74(1): 168-175.
|
| [3] |
Remerand G, Boespflug-Tanguy O, Tonduti D, et al. Expanding the phenotypic spectrum of Allan-Herndon-Dudley syndrome in patients with SLC16A2 mutations[J]. Dev Med Child Neurol, 2019, 61(12): 1439-1447.
|
| [4] |
Allan W, Herndon CN, Dudley FC. Some examples of the inheritance of mental deficiency: apparently sex-linked idiocy and microcephaly[J]. Am J Ment Defic, 1944, 48: 325-334.
|
| [5] |
Schwartz CE, May MM, Carpenter NJ, et al. Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene[J]. Am J Hum Genet, 2005, 77(1): 41-53.
|
| [6] |
Bernal J. Thyroid hormone receptors in brain development and function[J]. Nat Clin Pract Endocrinol Metab, 2007, 3(3): 249-259.
|
| [7] |
Friesema EC, Kuiper GG, Jansen J, et al. Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism[J]. Mol Endocrinol, 2006, 20(11): 2761-2772.
|
| [8] |
Vancamp P, Deprez MA, Remmerie M, et al. Deficiency of the thyroid hormone transporter monocarboxylate transporter 8 in neural progenitors impairs cellular processes crucial for early corticogenesis[J]. J Neurosci, 2017, 37(48): 11616-11631.
|
| [9] |
Wirth EK, Roth S, Blechschmidt C, et al. Neuronal 3’,3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome[J]. J Neurosci, 2009, 29(30): 9439-9449.
|
| [10] |
Biebermann H, Ambrugger P, Tarnow P, et al. Extended clinical phenotype, endocrine investigations and functional studies of a loss-of-function mutation A150V in the thyroid hormone specific transporter MCT8[J]. Eur J Endocrinol, 2005, 153(3): 359-366.
|
| [11] |
Novara F, Groeneweg S, Freri E, et al. Clinical and molecular characteristics of SLC16A2 (MCT8) mutations in three families with the Allan-Herndon-Dudley syndrome[J]. Hum Mutat, 2017, 38(3): 260-264.
|
| [12] |
Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation[J]. Lancet, 2004, 364(9443): 1435-1437.
|
| [13] |
Islam MS, Namba N, Ohata Y, et al. Functional analysis of monocarboxylate transporter 8 mutations in Japanese Allan-Herndon-Dudley syndrome patients[J]. Endocr J, 2019, 66(1): 19-29.
|
| [14] |
Frints SG, Lenzner S, Bauters M, et al. MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression[J]. Eur J Hum Genet, 2008, 16(9): 1029-1037.
|
| [15] |
Garcia-de Teresa B, Gonzalez-Del Angel A, Reyna-Fabian ME, et al. Deletion of exon 1 of the SLC16A2 gene: a common occurrence in patients with Allan-Herndon-Dudley syndrome[J]. Thyroid, 2015, 25(3): 361-367.
|
| [16] |
Ono E, Ariga M, Oshima S, et al. Three novel mutations of the MCT8 (SLC16A2) gene: individual and temporal variations of endocrinological and radiological features[J]. Clin Pediatr Endocrinol, 2016, 25(2): 23-35.
|
| [17] |
Boccone L, Mariotti S, Dessì V, et al. Allan-Herndon-Dudley syndrome (AHDS) caused by a novel SLC16A2 gene mutation showing severe neurologic features and unexpectedly low TRH-stimulated serum TSH[J]. Eur J Med Genet, 2010, 53(6): 392-395.
|
| [18] |
Kobayashi S, Onuma A, Inui T, et al. Clinical course and images of four familial cases of Allan-Herndon-Dudley syndrome with a novel monocarboxylate transporter 8 gene mutation[J]. Pediatr Neurol, 2014, 51(3): 414-416.
|
| [19] |
王佳平,章清萍,包新华,等.五例Allan-Herndon-Dudley综合征患儿的临床及遗传学特点分析[J].中华医学遗传学杂志, 2018, 35(4): 484-488.
|
| [20] |
唐玉琳,彭镜,熊娟,等. SLC16A2基因突变致Allan-Herndon-Dudley综合征一家系[J].中华儿科杂志, 2018, 56(11): 829-834.
|
| [21] |
Dumitrescu AM, Liao XH, Best TB, et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene[J]. Am J Hum Genet, 2004, 74(1): 168-175.
|
| [22] |
Anık A, Kersseboom S, Demir K, et al. Psychomotor retardation caused by a defective thyroid hormone transporter: report of two families with different MCT8 mutations[J]. Horm Res Paediatr, 2014, 82(4): 261-271.
|
| [23] |
Boccone L, Dessì V, Meloni A, et al. Allan-Herndon-Dudley syndrome (AHDS) in two consecutive generations caused by a missense MCT8 gene mutation. Phenotypic variability with the presence of normal serum T3 levels[J]. Eur J Med Genet, 2013, 56(4): 207-210.
|
| [24] |
Philips AK, Siren A, Avela K, et al. X-exome sequencing in finnish families with intellectual disability--four novel mutations and two novel syndromic phenotypes[J]. Orphanet J Rare Dis, 2014, 9: 49.
|
| [25] |
Fuchs O, Pfarr N, Pohlenz J, et al. Elevated serum triiodothyronine and intellectual and motor disability with paroxysmal dyskinesia caused by a monocarboxylate transporter 8 gene mutation[J]. Dev Med Child Neurol, 2009, 51(3): 240-244.
|
| [26] |
Verge CF, Konrad D, Cohen M, et al. Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency[J]. J Clin Endocrinol Metab, 2012, 97(12): 4515-4523.
|
| [27] |
Vancamp P, Darras VM. From zebrafish to human: a comparative approach to elucidate the role of the thyroid hormone transporter MCT8 during brain development[J]. Gen Comp Endocrinol, 2018, 265: 219-229.
|
| [28] |
Braun D, Schweizer U. The chemical chaperone phenylbutyrate rescues MCT8 mutations associated with milder phenotypes in patients with Allan-Herndon-Dudley syndrome[J]. Endocrinology, 2017, 158(3): 678-691.
|
| [29] |
Zada D, Tovin A, Lerer-Goldshtein T, et al. Altered behavioral performance and live imaging of circuit-specific neural deficiencies in a zebrafish model for psychomotor retardation[J]. PLoS Genet, 2014, 10(9): e1004615.
|
| [30] |
Lee JY, Kim MJ, Deliyanti D, et al. Overcoming monocarboxylate transporter 8 (MCT8)-deficiency to promote human oligodendrocyte differentiation and myelination[J]. EBioMedicine, 2017, 25: 122-135.
|
| [31] |
Ferrara AM, Liao XH, Ye H, et al. The thyroid hormone analog DITPA ameliorates metabolic parameters of male mice with MCT8 deficiency[J]. Endocrinology, 2015, 156(11): 3889-3894.
|
| [32] |
Barez-Lopez S, Grijota-Martinez C, Liao XH, et al. Intracerebroventricular administration of the thyroid hormone analog TRIAC increases its brain content in the absence of MCT8[J]. PLoS One, 2019, 14(12): e0226017.
|
| [33] |
Groeneweg S, Peeters RP, Visser TJ, et al. Triiodothyroacetic acid in health and disease[J]. J Endocrinol, 2017, 234(2): R99-R121.
|
| [34] |
Kersseboom S, Horn S, Visser WE, et al. In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency[J]. Mol Endocrinol, 2014, 28(12): 1961-1970.
|
| [35] |
Groeneweg S, Peeters RP, Moran C, et al. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial[J]. Lancet Diabetes Endocrinol, 2019, 7(9): 695-706.
|
| [36] |
Bauer AJ. Triac in the treatment of Allan-Herndon-Dudley syndrome[J]. Lancet Diabetes Endocrinol, 2019, 7(9): 661-663.
|